Reyhane Karegar-Niavol, Fatemeh Ghaffari, Ali Saravi, Zahra Fotokian, Farzan Kheirkhah
BACKGROUND: Valid and reliable instruments are needed to measure prostate cancer-related lifestyle changes, plan evidence-based interventions to modify lifestyle, and improve treatment outcomes. Due to the lack of appropriate instruments, this study was conducted to translate the Effects of Prostate Cancer upon Lifestyle Questionnaire (EPCLQ) into Persian and examine its psychometric properties in a sample of Iranian older adults with prostate cancer. METHODS: This methodological study was carried out between 2021 and 2022...
April 21, 2024: Prostate
Catherine H Marshall, Lukasz P Gondek, Violet Daniels, Changxue Lu, Sergiu Pasca, Jiajun Xie, Mark C Markowski, Channing J Paller, Laura A Sena, Samuel R Denmeade, Jun Luo, Emmanuel S Antonarakis
BACKGROUND: Poly ADP-ribose polymerase (PARP) inhibitors are approved for the treatment of some men with advanced prostate cancer. Rare but serious side effects include myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The impact of PARP inhibitors on clonal hematopoiesis (CH), a potential precursor lesion associated with MDS and AML, is incompletely understood in prostate cancer. We hypothesized that PARP inhibitors would increase CH prevalence and abundance. METHODS: We prospectively enrolled participants with advanced prostate cancer treated with PARP inhibitors...
April 20, 2024: Prostate
Tianwei Jia, Chenxu Liu, Ping Guo, Yaning Xu, Wenzheng Wang, Xiaoyu Liu, Song Wang, Xianglin Zhang, Haiyang Guo
BACKGROUND: Ribosome biogenesis is excessively activated in tumor cells, yet it is little known whether oncogenic transcription factors (TFs) are involved in the ribosomal RNA (rRNA) transactivation. METHODS: Nucleolar proteomics data and large-scale immunofluorescence were re-analyzed to jointly identify the proteins localized at nucleolus. RNA-Seq data of five prostate cancer (PCa) cohorts were combined and integrated with multi-dimensional data to define the upregulated nucleolar TFs in PCa tissues...
April 17, 2024: Prostate
Fengnian Zhao, Jinge Zhao, Xinyuan Wei, Yifu Shi, Nanwei Xu, Sha Zhu, Junru Chen, Guangxi Sun, Jindong Dai, Zhipeng Wang, Xingming Zhang, Jiayu Liang, Xu Hu, Haoyang Liu, Junjie Zhao, Zhenhua Liu, Ling Nie, Pengfei Shen, Ni Chen, Hao Zeng
BACKGROUND: KI67 is a well-known biomarker reflecting cell proliferation. We aim to elucidate the predictive role of KI67 in the efficacy of abiraterone for patients with advanced prostate cancer (PCa). METHODS: Clinicopathological data of 152 men with metastatic PCa, who received abiraterone therapy were retrospectively collected. The KI67 positivity was examined by immunohistochemistry using the prostate biopsy specimen. The predictive value of KI67 on the therapeutic efficacy of abiraterone was explored using Kaplan-Meier curve and Cox regression analysis...
April 17, 2024: Prostate
Eli Marie Grindedal, Manuela Zucknick, Astrid Stormorken, Elin Rønne, Nora M Tandstad, William B Isaacs, Karol Axcrona, Lovise Mæhle
BACKGROUND: Pathogenic germline variants in the mismatch repair (MMR) genes are associated with an increased risk of prostate cancer (PCa). Since 2010 we have recommended MMR carriers annual PSA testing from the age of 40. Prospective studies of the outcome of long-term PSA screening are lacking. This study aimed to investigate the incidence and characteristics of PCa in Norwegian MMR carriers attending annual PSA screening (PSA threshold >3.0 ng/mL) to evaluate whether our recommendations should be continued...
April 17, 2024: Prostate
Sumer Jasmine, Adel Mandl, Timothy E G Krueger, Susan L Dalrymple, Lizamma Antony, Jennifer Dias, Cassandra A Celatka, Amy E Tapper, Maria Kleppe, Mayuko Kanayama, Yuezhou Jing, Valentina Speranzini, Yuzhuo Z Wang, Jun Luo, Bruce J Trock, Samuel R Denmeade, Michael A Carducci, Andrea Mattevi, Hugh Y Rienhoff, John T Isaacs, W Nathaniel Brennen
INTRODUCTION: Lysine-specific demethylase 1 (LSD1) is emerging as a critical mediator of tumor progression in metastatic castration-resistant prostate cancer (mCRPC). Neuroendocrine prostate cancer (NEPC) is increasingly recognized as an adaptive mechanism of resistance in mCRPC patients failing androgen receptor axis-targeted therapies. Safe and effective LSD1 inhibitors are necessary to determine antitumor response in prostate cancer models. For this reason, we characterize the LSD1 inhibitor bomedemstat to assess its clinical potential in NEPC as well as other mCRPC pathological subtypes...
April 15, 2024: Prostate
Naz Chaudary, E Wiljer, Warren Foltz, Pratibha Thapa, Richard P Hill, Michael Milosevic
BACKGROUND: There are limited preclinical orthotopic prostate cancer models due to the technical complexity of surgical engraftment and tracking the tumor growth in the mouse prostate gland. Orthotopic xenografts recapitulate the tumor microenvironment, tumor stromal interactions, and clinical behavior to a greater extent than xenografts grown at subcutaneous or intramuscular sites. METHODS: This study describes a novel micro-surgical technique for orthotopically implanting intact tumors pieces from cell line derived (transgenic adenocarcinoma mouse prostate [TRAMP]-C2) or patient derived (neuroendocrine prostate cancer [NEPC]) tumors in the mouse prostate gland and monitoring tumor growth using magnetic resonance (MR) imaging...
April 12, 2024: Prostate
LaKendria K Brown, Thanigaivelan Kanagasabai, Guoliang Li, Sherly I Celada, Jelonia T Rumph, Samuel E Adunyah, LaMonica V Stewart, Zhenbang Chen
BACKGROUND: Prostate cancer (PCa) is the second-leading cause of cancer mortalities in the United States and is the most commonly diagnosed malignancy in men. While androgen deprivation therapy (ADT) is the first-line treatment option to initial responses, most PCa patients invariably develop castration-resistant PCa (CRPC). Therefore, novel and effective treatment strategies are needed. The goal of this study was to evaluate the anticancer effects of the combination of two small molecule inhibitors, SZL-P1-41 (SKP2 inhibitor) and PBIT (KDM5B inhibitor), on PCa suppression and to delineate the underlying molecular mechanisms...
April 11, 2024: Prostate
Kei-Ichiro Uemura, Akinobu Togo, Tasuku Hiroshige, Keisuke Ohta, Kosuke Ueda, Kiyoaki Nishihara, Makoto Nakiri, Shingo Hirashima, Tsukasa Igawa, Kei-Ichiro Nakamura
BACKGROUND: A few studies have examined the ultrastructure of prostatic neuroendocrine cells (NECs), and no study has focused on their ultrastructure in three dimensions. In this study, three-dimensional ultrastructural analysis of mouse prostatic NECs was performed to clarify their anatomical characteristics. METHODS: Three 13-week-old male C57BL/6 mice were deeply anesthetized, perfused with physiological saline and 2% paraformaldehyde, and then placed in 2.5% glutaraldehyde in 0...
April 8, 2024: Prostate
Enrico Checcucci, Sabrina De Cillis, Eugenio Alladio, Federico Piramide, Gabriele Volpi, Stefano Granato, Davide Zamengo, Gabriele Bignante, Daniele Amparore, Alberto Piana, Matteo Manfredi, Edoardo Vallariello, Ilaria Stura, Michele Di Dio, Riccardo Autorino, Francesco Porpiglia, Cristian Fiori
BACKGROUND: Among prostate cancer (PCa) treatment options, mini-invasive surgical approaches have gained a wide diffusion in the last decades. The aim of this study was to present oncological, functional, and quality of life data after 10 years of follow-up of a prospective randomized controlled trial (RCT) (ISRCTN11552140) comparing robot-assisted radical prostatectomy (RARP) versus laparoscopic radical prostatectomy (LRP) for the treatment of PCa. METHODS: Patients with localized PCa were randomized to undergo LRP or RARP between January 2010 and January 2011...
April 4, 2024: Prostate
Nicolas Martelin, Brian De Witt, Benjamin Chen, Pascal Eschwège
PURPOSE: Prostate specific antigen (PSA) testing is a low-cost screening method for prostate cancer (PCa). However, its accuracy is limited. While progress is being made using medical imaging for PCa screening, PSA testing can still be improved as an easily accessible first step in the screening process. We aimed to develop and validate a new model by further personalizing the analysis of PSA with demographic, medical history, lifestyle parameters, and digital rectal examination (DRE) results...
April 4, 2024: Prostate
Irvin M Modlin, Mark Kidd, Ignat A Drozdov, Martin Boegemann, Lisa Bodei, Jolanta Kunikowska, Anna Malczewska, Christof Bernemann, Srinivas V Koduru, Kambiz Rahbar
INTRODUCTION: We describe the development of a molecular assay from publicly available tumor tissue mRNA databases using machine learning and present preliminary evidence of functionality as a diagnostic and monitoring tool for prostate cancer (PCa) in whole blood. MATERIALS AND METHODS: We assessed 1055 PCas (public microarray data sets) to identify putative mRNA biomarkers. Specificity was confirmed against 32 different solid and hematological cancers from The Cancer Genome Atlas (n = 10,990)...
April 3, 2024: Prostate
Georges Gebrael, Chadi Hage Chehade, Nicolas Sayegh, Nishita Tripathi, Beverly Chigarira, Divyam Goel, Blake Nordblad, Taylor R McFarland, Arshit Narang, Ayana Srivastava, Clara Tandar, Emre Dal, Yeonjung Jo, Gliceida Galarza Fortuna, Vinay Mathew Thomas, Kamal K Sahu, Haoran Li, Benjamin L Maughan, Umang Swami, Neeraj Agarwal
BACKGROUND: Androgen deprivation therapy (ADT) intensification (ADTi) (i.e., ADT with androgen receptor pathway inhibitor or docetaxel, or both) has significantly improved survival outcomes of patients with metastatic hormone-sensitive prostate cancer (mHSPC). However, the impact of prior ADTi in the mHSPC setting on the disease presentation and survival outcomes in metastatic castration-resistant prostate cancer (mCRPC) is not well characterized. In this study, our objective was to compare the disease characteristics and survival outcomes of patients with new mCRPC with respect to receipt of intensified or nonintensified ADT in the mHSPC setting...
April 1, 2024: Prostate
Jimin Kim, Sanghee Park, Seunghwan Kim, Seungyeon Ryu, Hyemin Hwang, Sua Cho, Yeonju Han, Jisu Kim, Yusun Park, Eun Kyung Lee, Misu Lee
BACKGROUND: Tumor initiation and progression necessitate a metabolic shift in cancer cells. Consequently, the progression of prostate cancer (PCa), a leading cause of cancer-related deaths in males globally, involves a shift from lipogenic to glycolytic metabolism. Androgen deprivation therapy (ADT) serves as the standard treatment for advanced-stage PCa. However, despite initial patient responses, castrate resistance emerges ultimately, necessitating novel therapeutic approaches. Therefore, in this study, we aimed to investigate the role of monocarboxylate transporters (MCTs) in PCa post-ADT and evaluate their potential as therapeutic targets...
April 1, 2024: Prostate
Qifei Dong, Changming Wang, Deyun Shen, Yifan Ma, Bin Zhang, Siqin Xu, Tao Tao, Jun Xiao
BACKGROUND: Nowadays, there are many patients who undergo unnecessary prostate biopsies after receiving a prostate imaging reporting and data system (PI-RADS) score of 3. Our purpose is to identify cutoff values of the prostate volume (PV) and minimum apparent diffusion coefficient (ADCmin ) to stratify those patients to reduce unnecessary prostate biopsies. METHODS: Data from 224 qualified patients who received prostate biopsies from January 2019 to June 2023 were collected...
April 1, 2024: Prostate
Hui-Chen Ku, Evelyn Cheng, Ching-Feng Cheng
BACKGROUND: Prostate cancer (PCa) is a common malignancy in males and obesity may play a role in its development and progression. Associations between visceral obesity measured by a body shape index (ABSI) and PCa mortality have not been thoroughly investigated. This study assessed the associations between ABSI, body mass index (BMI), and long-term PCa-specific mortality using a nationally representative US database. METHODS: This population-based longitudinal study collected data of males aged ≥40 years diagnosed with PCa and who underwent surgery and/or radiation from the National Health and Nutrition Examination Survey database 2001-2010...
April 1, 2024: Prostate
Chinade Roper, Austen Slade, Ronald Caras, Thomas Shelton, Marcelino Rivera
PURPOSE: Holmium laser enucleation of the prostate (HoLEP) is a surgical treatment option for benign prostatic hyperplasia (BPH). Many men develop retrograde ejaculation postprocedure, but there is conflicting evidence regarding sexual function outcomes post-HoLEP. We sought to examine significant variations in patient-reported erectile and ejaculatory function within 12 months post-HoLEP. MATERIALS AND METHODS: We conducted a retrospective study for patients who underwent HoLEP between Nov 2018 and Feb 2022...
April 1, 2024: Prostate
YuNing Zhang, Yijie Dong, Zihan Mei, Yiqing Hou, Minyan Wei, Yat Hin Yeung, Jiale Xu, Qing Hua, LiMei Lai, Ning Li, ShuJun Xia, Chun Zhou, JianQiao Zhou
BACKGROUND: Benign prostatic hyperplasia (BPH) is a common condition, yet it is challenging for the average BPH patient to find credible and accurate information about BPH. Our goal is to evaluate and compare the accuracy and reproducibility of large language models (LLMs), including ChatGPT-3.5, ChatGPT-4, and the New Bing Chat in responding to a BPH frequently asked questions (FAQs) questionnaire. METHODS: A total of 45 questions related to BPH were categorized into basic and professional knowledge...
April 1, 2024: Prostate
Mohammed Shahait, Alexander K Hakansson, Reba E Daniel, Kareem Hosny, Elai Davicioni, Seagle Yang Liu, Alex Sandberg, David I Lee, Priti Lal
OBJECTIVE: To morphologically describe tertiary lymphoid structures (TLS) in prostatectomy specimens and correlate them with clinical and transcriptomic features. METHODOLOGY: A total of 72 consecutive cases of entirely submitted radical prostatectomy (RP) patients tested with the Decipher Genomic Classifier were included in the study. Images were manually annotated using QuPath tools to denote tumor regions and each cluster of TLS. Clusters of lymphocytes that were surrounded on all four sides by tumor were defined as intra-tumor TLS (IT-TLS)...
March 27, 2024: Prostate
Kate L Mahon, Sarah Im Sutherland, Hui Ming Lin, Martin R Stockler, Howard Gurney, Girish Mallesara, Karen Briscoe, Gavin Marx, Celestia S Higano, Johann S de Bono, Kim N Chi, Georgina Clark, Samuel N Breit, David A Brown, Lisa G Horvath
BACKGROUND: Elevated circulating growth differentiation factor (GDF15/MIC-1), interleukin 4 (IL4), and IL6 levels were associated with resistance to docetaxel in an exploratory cohort of men with metastatic castration-resistant prostate cancer (mCRPC). This study aimed to establish level 2 evidence of cytokine biomarker utility in mCRPC. METHODS: IntVal: Plasma samples at baseline (BL) and Day 21 docetaxel (n = 120). ExtVal: Serum samples at BL and Day 42 of docetaxel (n = 430)...
March 27, 2024: Prostate
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.